Table 1.
Characteristics and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection stratified by vaccination status
| Covariate/Outcome | Unvaccinated | First Dose (>10 d After) | Second Dose (>10 d After) | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Number/ Median | Percentage/ IQR | Number/ Median | Percentage/ IQR | Number/ Median | Percentage/ IQR | Number/ Median | Percentage/ IQR | |
| N | 1047 | 86 | 190 | 1323 | ||||
| Days after dose, median (IQR) | 25.5 | (18–52) | 126.5 | (95–153) | ||||
| Vaccine | ||||||||
| BNT162b2 | 46 | (53) | 79 | (42) | ||||
| AZD1222 | 38 | (44) | 107 | (56) | ||||
| Age, median (IQR) | 61 | (53–72) | 71 | (58–79) | 63 | (52–73) | 62 | (53–73) |
| Sex | ||||||||
| Men | 622 | (59) | 58 | (67) | 117 | (62) | 797 | (60) |
| Ethnicity | ||||||||
| Asian/other | 332 | (32) | 16 | (19) | 50 | (26) | 398 | (30) |
| Black | 401 | (38) | 28 | (33) | 79 | (42) | 508 | (38) |
| White | 314 | (30) | 42 | (49) | 61 | (32) | 417 | (32) |
| Diabetes | 484 | (46) | 42 | (49) | 93 | (49) | 619 | (47) |
| Immune suppressiona | 117 | (11) | 14 | (16) | 33 | (17) | 164 | (12) |
| Prior SARS-CoV-2b | 29 | (3) | 4 | (5) | 12 | (6) | 45 | (3) |
| Outcome | ||||||||
| Admissionc | 436 | (42) | 33 | (38) | 46 | (24) | 515 | (39) |
| Oxygend | 329 | (31) | 23 | (27) | 26 | (14) | 378 | (29) |
| Ventilationd | 185 | (18) | 17 | (20) | 18 | (10) | 220 | (17) |
| Deathd | 148 | (14) | 12 | (14) | 12 | (6) | 172 | (13) |
Except where stated, data are N (%). Clinical outcomes are “all cause,” not specifically due to coronavirus disease 2019. IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Any immune suppression treatment including steroids, tacrolimus, mycophenolate, azathioprine, and cytotoxic and biologic agents.
b
PCR positive at least 90 days prior to the current infection.
c
Within 14 days of positive PCR.
d
Within 28 days of positive PCR.